NCT04562441 2025-01-10NPC - AXEL Study : Axitinib-AvelumabChinese University of Hong KongPhase 2 Completed13 enrolled
NCT03941262 2023-11-13Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional TherapyNKGen Biotech, Inc.Phase 1 Completed27 enrolled
NCT02625623 2020-11-24Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)EMD SeronoPhase 3 Completed371 enrolled 18 charts